PTC Therapeutics announced the acquisition of ST-920, a BLA-stage gene therapy for Fabry disease, for $111 million upfront and up to $100 million in contingent milestones. This strategic acquisition expands PTC's pipeline in rare diseases and leverages its existing infrastructure, with a BLA submission expected in Q4 2026 and potential commercial launch in 2027.
PTC Therapeutics has acquired ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a bankruptcy auction. This is a significant strategic move for PTC, as it adds a late-stage, potentially high-value asset to its rare disease pipeline, leveraging its existing regulatory and commercial infrastructure. For Sangamo, this sale provides much-needed liquidity during its bankruptcy proceedings. In the short term, this could be seen as positive for PTCT due to pipeline expansion and potential future revenue, and for SGMO as it addresses financial distress. Long-term, the success of ST-920's BLA submission and commercialization will be crucial for PTCT, while SGMO's future depends on its broader restructuring efforts. The key opportunity for traders is the potential upside for PTCT if ST-920 gains approval and market traction, and for SGMO, the immediate relief from asset sale.